Skip to main content
SpringerLink
Log in

Medical Treatment of Stable Angina

  • Chapter
Cardiovascular Medicine

  • 211 Accesses

Abstract

  • Therapy is directed at reducing heart rate, blood pressure, and contractile responses to exercise and stress, so that myocardial oxygen demand for any given activity is reduced. Medication and interventions that increase coronary blood flow and oxygen delivery may also be useful.

  • The heart rate-systolic blood pressure product provides an estimate of myocardial oxygen demand.

  • Stable angina can usually be relieved promptly by rest and nitroglycerin.

  • Exogenously administered nitrates increase oxygen delivery to the subendocardial region supplied by a severely narrowed coronary artery.

  • One should not use nitrates and erectile dysfunction medications (sildenafil, vardenafil, or tadalafil) within 24 hours of one another as the combination may cause profound hypotension.

  • β-adrenergic antagonists attenuate heart rate, systolic blood pressure, and contractile responses at rest and during exercise.

  • Selected beta-blockers reduce mortality and repeated hospitalization risks in patients with prior myocardial infarctions, heart failure, and hypertension.

  • Beta-blockers may cause bradycardia, bronchospasm, hypotension, atrioventricular (AV) block, and depression of myocardial contractility. They may also exacerbate coronary artery spasm and make it more frequent and severe.

  • Slow calcium channel antagonists relax vascular smooth muscle and increase coronary blood flow. They are divided into two major classes: dihydropyridines (nifedipine and amlodipine) and the nondihydropyridines (diltiazem and verapamil). The nondihydropyridine calcium antagonists decrease AV conduction and sinus node impulse formation while increasing coronary blood flow. The dihydropyridine calcium antagonists do not decrease AV conduction and sinus impulse formation but do increase coronary blood flow.

  • The nondihydropyridines have significant negative inotropic effects and should not be given to patients with clinically significant congestive heart failure (CHF).

  • Angiotensin-converting enzyme (ACE) inhibitors may improve endothelial function in patients with stable coronary heart disease.

  • The risk of myocardial infarction in patients with coronary heart disease is reduced with aspirin.

  • Meta-analysis in various clinical studies have suggested 75 to 150 mg of aspirin daily in patients at high risk for myocardial infarction.

  • Clopidogrel in combination with aspirin may be bene- ficial in those patients with established coronary disease.

  • To date, oral IIb/IIIa platelet antagonists have not been protective, and some studies show possible harm.

  • Chronic oral anticoagulation therapy after myocardial infarction reduces the combined end points of mortality and nonfatal reinfarction while increasing bleeding risks.

  • Patients with known or suspected coronary heart disease should avoid smoking, rigorously control their serum cholesterol with the lowest low-density lipoprotein (LDL) possible, reduce their triglycerides, control their blood pressure and hyperglycemia, and get regular exercise.

  • Evidence suggests that estrogen and progestin do not prevent clinically significant coronary heart disease.

  • The cyclooxygenase (COX-2) inhibitors that increase blood pressure appear to slightly increase the risk of future vascular events (i.e., valdecoxib). Other COX-2 inhibitors used in low dose, such as celecoxib probably do not signifi cantly increase the risk of future vascular events.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Danahy DT, Aronow WS. Hemodynamics and antianginal effects of high dose oral isosorbide dinitrate after chronic use. Circulation 1977;56(2):205–212.

    PubMed  CAS  Google Scholar 

  2. Glancy DL, Richter MA, Ellis EV, et al. Effect of swallowed isosorbide dinitrate on blood pressure, heart rate and exercise capacity in patients with coronary artery disease. Am J Med 1977;62(1):39–46.

    PubMed  CAS  Google Scholar 

  3. Horowitz JD, Antman EM, Lorell BH, et al. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation 1983;68(6):1247–1253.

    PubMed  CAS  Google Scholar 

  4. Markis JE, Gorlin R, Mills RM, et al. Sustained effect of orally administered isosorbide dinitrate on exercise performance of patients with angina pectoris. Am J Cardiol 1979;43(2):265–271.

    PubMed  CAS  Google Scholar 

  5. Mason DT, Braunwald E. The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. Circulation 1965;32(5):755–766.

    PubMed  CAS  Google Scholar 

  6. Murad F, Arnold WP, Mittal CK, et al. Properties and regulation of guanylate cyclase and some proposed functions for cyclic GMP. Adv Cyclic Nucleotide Res 1979;11:175–204.

    PubMed  CAS  Google Scholar 

  7. Parker JO, VanKoughnett KA, Fung HL. Transdermal isosorbide dinitrate in angina pectoris: effect of acute and sustained therapy. Am J Cardiol 1984;54(1):8–13.

    PubMed  CAS  Google Scholar 

  8. Reichek N, Priest C, Zimrin D, et al. Antianginal effects of nitroglycerin patches. Am J Cardiol 1984;54(1):1–7.

    PubMed  CAS  Google Scholar 

  9. Thadani U, Fung HL, Darke AC, et al. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an doseresponse relation during acute and sustained therapy. Am J Cardiol 1982;49(2):411–419.

    PubMed  CAS  Google Scholar 

  10. Abrams J. Nitrate tolerance and dependence. Am Heart J 1980;99(1):113–123.

    PubMed  CAS  Google Scholar 

  11. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973;184(3):709–715.

    PubMed  CAS  Google Scholar 

  12. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999;33(1):273–282.

    PubMed  CAS  Google Scholar 

  13. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560–2572.

    PubMed  CAS  Google Scholar 

  14. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001;38(5):1581–1583.

    PubMed  Google Scholar 

  15. Conolly ME, Kersting F, Dollery CT. The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis 1976;19(3):203–234.

    PubMed  CAS  Google Scholar 

  16. Dreyfuss J, Brannick LJ, Vukovich RA, et al. Metabolic studies in patients with nadolol: oral and intravenous administration. J Clin Pharmacol 1977;17(5–6):300–307.

    PubMed  CAS  Google Scholar 

  17. Frishman W. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties. Am Heart J 1979;97(5):663–670.

    PubMed  CAS  Google Scholar 

  18. Frishman W. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 9. Nadolol: a new long-acting beta-adrenoceptor blocking drug. Am Heart J 1980;99(1):124–128.

    PubMed  CAS  Google Scholar 

  19. Koch-Weser J. Drug therapy: metoprolol. N Engl J Med 1979;301(13):698–703.

    PubMed  CAS  Google Scholar 

  20. Koch-Weser J, Frishman WH. Beta-adrenoceptor antagonists: new drugs and new indications. N Engl J Med 1981;305(9):500–506.

    PubMed  CAS  Google Scholar 

  21. Moses JW, Borer JS. Beta-adrenergic antagonists in the treatment of patients with heart disease. Dis Mon 1981;27(9):1–61.

    PubMed  CAS  Google Scholar 

  22. Opie LH. Drugs and the heart. Lancet 1980;1(8170):693–698.

    PubMed  CAS  Google Scholar 

  23. Andreasen F, Boye E, Christoffersen E, et al. Assessment of verapamil in the treatment of angina pectoris. Eur J Cardiol 1975;2(4):443–452.

    PubMed  CAS  Google Scholar 

  24. Balasubramanian V, Khanna PK, Naryanan GR, et al. Verapamil in ischaemic heart disease—quantitative assessment by serial multistage treadmill exercise. Postgrad Med J 1976;52(605):143–147.

    PubMed  CAS  Google Scholar 

  25. Forman R, Eng C, Kirk ES. Comparative effect of verapamil and nitroglycerin on collateral blood flow. Circulation 1983;67(6):1200–1204.

    PubMed  CAS  Google Scholar 

  26. Freedman B, Dunn RF, Richmond DR, et al. Coronary artery spasm during exercise: treatment with verapamil. Circulation 1981;64(1):68–75.

    PubMed  CAS  Google Scholar 

  27. Gunther S, Green L, Muller JE, et al. Prevention of nifedipine of abnormal coronary vasoconstriction in patients with coronary artery disease. Circulation 1981;63(4):849–855.

    PubMed  CAS  Google Scholar 

  28. Hansen JF, Sandoe E. Treatment of Prinzmetal’s angina due to coronary artery spasm using verapamil: a report of three cases. Eur J Cardiol 1978;7(4):327–335.

    PubMed  CAS  Google Scholar 

  29. Heng MK, Singh BN, Roche AH, et al. Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. Am Heart J 1975;90(4):487–498.

    PubMed  CAS  Google Scholar 

  30. Hillis LD. The new coronary vasodilators: calcium blockers. Journal of Cardiovascular Medicine 1980;5:583.

    Google Scholar 

  31. Hugenholtz PG, Michels HR, Serruys PW, et al. Nifedipine in the treatment of unstable angina, coronary spasm and myocardial ischemia. Am J Cardiol 1981;47(1):163–173.

    PubMed  CAS  Google Scholar 

  32. Johnson SM, Mauritson DR, Corbett JR, et al. Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med 1981;71(3):443–451.

    PubMed  CAS  Google Scholar 

  33. Johnson SM, Mauritson DR, Willerson JT, et al. A controlled trial of verapamil for Prinzmetal’s variant angina. N Engl J Med 1981;304(15):862–866.

    PubMed  CAS  Google Scholar 

  34. Johnson SM, Mauritson DR, Willerson JT, et al. Comparison of verapamil and nifedipine in the treatment of variant angina pectoris: preliminary observations in 10 patients. Am J Cardiol 1981;47(6):1295–1300.

    PubMed  CAS  Google Scholar 

  35. Livesley B, Catley PF, Campbell RC, et al. Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. Br Med J 1973;1(5850):375–378.

    PubMed  CAS  Google Scholar 

  36. Muller JE, Gunther SJ. Nifedipine therapy for Prinzmetal’s angina. Circulation 1978;57(1):137–139.

    PubMed  CAS  Google Scholar 

  37. Nagao T, Ikeo T, Sato M. Influence of calcium ions on responses to diltiazem in coronary arteries. Jpn J Pharmacol 1977;27(2):330–332.

    PubMed  CAS  Google Scholar 

  38. Neumann M, Luisada AA. Double blind evaluation of orally administered iproveratril in patients with angina pectoris. Am J Med Sci 1966;251(5):552–556.

    PubMed  CAS  Google Scholar 

  39. Previtali M, Salerno JA, Tavazzi L, et al. Treatment of angina at rest with nifedipine: a short-term controlled study. Am J Cardiol 1980;45(4):825–830.

    PubMed  CAS  Google Scholar 

  40. Sandler G, Clayton GA, Thornicroft SG. Clinical evaluation of verapamil in angina pectoris. Br Med J 1968;3(612):224–227.

    PubMed  CAS  Google Scholar 

  41. Schamroth L. Immediate effects of intravenous verapamil on atrial fibrillation. Cardiovasc Res 1971;5(4):419–424.

    PubMed  CAS  Google Scholar 

  42. Schroeder JS, Lamb IH, Ginsburg R, et al. Diltiazem for longterm therapy of coronary arterial spasm. Am J Cardiol 1982;49(3):533–537.

    PubMed  CAS  Google Scholar 

  43. Solberg LE, Nissen RG, Vlietstra RE, et al. Prinzmetal’s variant angina—response to verapamil. Mayo Clin Proc 1978;53(4):256–259.

    PubMed  CAS  Google Scholar 

  44. Theroux P, Waters DD, Affaki GS, et al. Provocative testing with ergonovine to evaluate the efficacy of treatment with calcium antagonists in variant angina. Circulation 1979;60(3):504–510.

    PubMed  CAS  Google Scholar 

  45. Weishaar R, Ashikawa K, Bing RJ. Effect of diltiazem, a calcium antagonist, on myocardial ischemia. Am J Cardiol 1979;43(6):1137–1143.

    PubMed  CAS  Google Scholar 

  46. Winniford MD, Johnson SM, Mauritson DR, et al. Verapamil therapy for Prinzmetal’s variant angina: comparison with placebo and nifedipine. Am J Cardiol 1982;50(4):913–918.

    PubMed  CAS  Google Scholar 

  47. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292(18):2217–2225.

    PubMed  CAS  Google Scholar 

  48. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92(5):1326–1331.

    PubMed  CAS  Google Scholar 

  49. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94(3):258–265.

    PubMed  CAS  Google Scholar 

  50. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145–153.

    PubMed  CAS  Google Scholar 

  51. Fox KM, Henderson JR, Bertrand ME, et al. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998;19(suppl J):J52–55.

    PubMed  CAS  Google Scholar 

  52. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351(20):2058–2068.

    PubMed  CAS  Google Scholar 

  53. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists’ Collaboration. Br Med J (Clin Res Ed) 1988;296(6618):320–331.

    Google Scholar 

  54. Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989;321(3):129–135.

    Google Scholar 

  55. Klimt CR, Knatterud GL, Stamler J, et al. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986;7(2):251–269.

    PubMed  CAS  Google Scholar 

  56. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296(6618):313–316.

    CAS  Google Scholar 

  57. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994;308(6921):81–106.

    Google Scholar 

  58. Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists’ Collaboration. BMJ 1994;308(6922):159–168.

    Google Scholar 

  59. Collaborative overview of randomised trials of antiplatelet therapy-III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration. BMJ 1994;308(6923):235–246.

    Google Scholar 

  60. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71–86.

    Google Scholar 

  61. Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and highdose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999;353(9171):2179–2184.

    PubMed  CAS  Google Scholar 

  62. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342(24):1773–1777.

    PubMed  CAS  Google Scholar 

  63. Ferguson J. Clopidogrel. In: Braunwald E, ed. Harrison’s Advances in Cardiology. New York: McGraw-Hill, 2002:144–154.

    Google Scholar 

  64. Kupfer Y, Tessler S. Ticlopidine and thrombotic thrombocytopenic purpura. N Engl J Med 1997;337(17):1245.

    PubMed  CAS  Google Scholar 

  65. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30(11):1288–1295.

    PubMed  CAS  Google Scholar 

  66. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84(5):891–896.

    PubMed  CAS  Google Scholar 

  67. Schror K. The basic pharmacology of ticlodipine and clopidogrel. Platelets 1993;4:252–261.

    Google Scholar 

  68. Schror K. Ticlopidine and Clopidogrel. In: Ferguson J, Chronos NAF, Harrington RA, ed. Antiplatelet Therapy in Clinical Practice. London: Martin Duntz, 2000:93–113.

    Google Scholar 

  69. Weber AA, Reimann S, Schror K. Specific inhibition of ADPinduced platelet aggregation by clopidogrel in vitro. Br J Pharmacol 1999;126(2):415–420.

    PubMed  CAS  Google Scholar 

  70. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1(8649):1215–1220.

    PubMed  CAS  Google Scholar 

  71. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321(8):501–507.

    PubMed  CAS  Google Scholar 

  72. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348(9038):1329–1339.

    Google Scholar 

  73. Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103(3):363–368.

    PubMed  CAS  Google Scholar 

  74. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90(6):625–628.

    PubMed  Google Scholar 

  75. Ferguson JJ VR, Massin EK. The effect of clopidogrel vs. aspirin on recurrent clinical events and mortality: results from the CAPRIE study. J Am Coll Cardiol 2001;37(2, suppl A):36A.

    Google Scholar 

  76. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494–502.

    PubMed  CAS  Google Scholar 

  77. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527–533.

    PubMed  CAS  Google Scholar 

  78. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354(16):1706–1717.

    PubMed  CAS  Google Scholar 

  79. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomized trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Postacute Coronary Syndromes. Lancet 2000;355(9201):337–345.

    Google Scholar 

  80. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001;103(13):1727–1733.

    Google Scholar 

  81. O’Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 2000;342(18):1316–1324.

    PubMed  CAS  Google Scholar 

  82. Topol EJ, Easton D, Harrington RA, et al. Randomized, doubleblind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108(4):399–406.

    PubMed  CAS  Google Scholar 

  83. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001;103(2):201–206.

    PubMed  CAS  Google Scholar 

  84. Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003;107(12):1692–1711.

    PubMed  Google Scholar 

  85. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978;17(8):1371–1377.

    PubMed  CAS  Google Scholar 

  86. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998;351(9098):233–241.

    Google Scholar 

  87. Cairns JA, Hirsh J, Lewis HD Jr, et al. Antithrombotic agents in coronary artery disease. Chest 1992;102(4 suppl):456S–481S.

    PubMed  CAS  Google Scholar 

  88. Goldberg RJ, Gore JM, Dalen JE, et al. Long-term anticoagulant therapy after acute myocardial infarction. Am Heart J 1985;109(3 pt 1):616–622.

    PubMed  CAS  Google Scholar 

  89. Leizorovicz A, Boissel JP. Oral anticoagulant in patients surviving myocardial infarction. A new approach to old data. Eur J Clin Pharmacol 1983;24(3):333–336.

    PubMed  CAS  Google Scholar 

  90. Chalmers TC, Matta RJ, Smith H Jr, et al. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297(20):1091–1096.

    PubMed  CAS  Google Scholar 

  91. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. Lancet 1980;2(8202):989–994.

    Google Scholar 

  92. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323(3):147–152.

    PubMed  CAS  Google Scholar 

  93. Ferguson J. Meeting Highlights: Highlights of the XXIII Congress of the European Society of Cardiology. Circulation 2001;104:e111–e116.

    Google Scholar 

  94. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet 1997;350(9075):389–396.

    Google Scholar 

  95. Fiore LD, Ezekowitz MD, Brophy MT, et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002;105(5):557–563.

    PubMed  CAS  Google Scholar 

  96. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003;41(4 suppl S):62S–69S.

    PubMed  CAS  Google Scholar 

  97. Williams MA, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002;105(14):1735–1743.

    PubMed  Google Scholar 

  98. Mamun AA, Peeters A, Barendregt J, et al. Smoking decreases the duration of life lived with and without cardiovascular disease: a life course analysis of the Framingham Heart Study. Eur Heart J 2004;25(5):409–415.

    PubMed  Google Scholar 

  99. Godtfredsen NS, Holst C, Prescott E, et al. Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 2002;156(11):994–1001.

    PubMed  Google Scholar 

  100. Sparrow D, Dawber TR. The influence of cigarette smoking on prognosis after a first myocardial infarction. A report from the Framingham study. J Chronic Dis 1978;31(6–7):425–432.

    PubMed  CAS  Google Scholar 

  101. The World Health Report 2002. Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: The World Health Organization, 2002.

    Google Scholar 

  102. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903–1913.

    PubMed  Google Scholar 

  103. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981–2997.

    Google Scholar 

  104. Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000;35(2):539–543.

    PubMed  CAS  Google Scholar 

  105. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336(16):1117–1124.

    PubMed  CAS  Google Scholar 

  106. Willett WC, Sacks F, Trichopoulou A, et al. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr 1995;61(6 Suppl):1402S–1406S.

    PubMed  CAS  Google Scholar 

  107. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99(6):779–785.

    PubMed  Google Scholar 

  108. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004;292(12):1433–1439.

    PubMed  Google Scholar 

  109. Dansinger ML, Gleason JA, Griffith JL, et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005;293(1):43–53.

    PubMed  CAS  Google Scholar 

  110. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383–1389.

    Google Scholar 

  111. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001–1009.

    PubMed  CAS  Google Scholar 

  112. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301–1307.

    PubMed  CAS  Google Scholar 

  113. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–3421.

    Google Scholar 

  114. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22.

    Google Scholar 

  115. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495–1504.

    PubMed  CAS  Google Scholar 

  116. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291(9):1071–1080.

    PubMed  CAS  Google Scholar 

  117. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292(11):1307–1316.

    PubMed  Google Scholar 

  118. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341(2):70–76.

    PubMed  CAS  Google Scholar 

  119. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109(3):433–438.

    PubMed  Google Scholar 

  120. Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111(11):1448–1454.

    PubMed  Google Scholar 

  121. Grundy SM, Hansen B, Smith SC Jr, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109(4):551–556.

    PubMed  Google Scholar 

  122. Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circulation 2003;108(13):1552–1553.

    PubMed  Google Scholar 

  123. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003;108(13):1546–1551.

    PubMed  Google Scholar 

  124. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005;48(9):1684–1699.

    PubMed  CAS  Google Scholar 

  125. Kantrowitz A. Experimental augmentation of coronary flow by retardation of the arterial pressure pulse. Surgery 1953;34(4):678–687.

    PubMed  CAS  Google Scholar 

  126. Singh M, Holmes DR Jr, Tajik AJ, et al. Noninvasive revascularization by enhanced external counterpulsation: a case study and literature review. Mayo Clin Proc 2000;75(9):961–965.

    PubMed  CAS  Google Scholar 

  127. Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 1999;33(7):1833–1840.

    PubMed  CAS  Google Scholar 

  128. Urano H, Ikeda H, Ueno T, et al. Enhanced external counter-pulsation improves exercise tolerance, reduces exercise-induced myocardial ischemia and improves left ventricular diastolic filling in patients with coronary artery disease. J Am Coll Cardiol 2001;37(1):93–99.

    PubMed  CAS  Google Scholar 

  129. Arora RR, Lopez S, Saric M. Enhanced external counterpulsation improves systolic function by echocardiography in patients with coronary artery disease. Heart Lung 2005;34(2):122–125.

    PubMed  Google Scholar 

  130. Kern MJ, Aguirre FV, Tatineni S, et al. Enhanced coronary blood flow velocity during intraaortic balloon counterpulsation in critically ill patients. J Am Coll Cardiol 1993;21(2):359–368.

    PubMed  CAS  Google Scholar 

  131. Sessa WC, Pritchard K, Seyedi N, et al. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994;74(2):349–353.

    PubMed  CAS  Google Scholar 

  132. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273(3):199–208.

    Google Scholar 

  133. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340(23):1801–1811.

    PubMed  CAS  Google Scholar 

  134. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280(7):605–613.

    PubMed  CAS  Google Scholar 

  135. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and bene-fits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288(3):321–333.

    PubMed  CAS  Google Scholar 

  136. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291(14):1701–1712.

    PubMed  CAS  Google Scholar 

  137. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353(9149):307–314.

    PubMed  CAS  Google Scholar 

  138. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345(6):433–442.

    PubMed  CAS  Google Scholar 

  139. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2(11):879–890.

    PubMed  CAS  Google Scholar 

  140. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343(21):1520–1528, 1522 p following 1528.

    PubMed  CAS  Google Scholar 

  141. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352(11):1092–1102.

    PubMed  CAS  Google Scholar 

  142. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352(11):1071–1080.

    PubMed  CAS  Google Scholar 

  143. NIH. Use of non-steroidal anti-Inflammatory drugs suspended in large Alzheimer’s disease prevention trial. http://www.nih.gov/news/or/dec2004/od-20.htm.

    Google Scholar 

  144. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005;112(5):759–770.

    PubMed  CAS  Google Scholar 

  145. Antzelvitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal egent with antiarrhythmic properties. Circulation 2004;110:904–910.

    Google Scholar 

  146. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375–1382.

    PubMed  CAS  Google Scholar 

  147. Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005;95:311–316.

    PubMed  CAS  Google Scholar 

  148. Pepine CJ, Wolff AA, Ranolazine Study Group. A controlled trial with a novel antiischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol 1999;84:46–50.

    PubMed  CAS  Google Scholar 

  149. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and anginal frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309–316.

    PubMed  CAS  Google Scholar 

  150. Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine in the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566–575.

    PubMed  CAS  Google Scholar 

  151. Cairns JA. Ranolazine: Augmenting the antianginal armamentarium. J Am Coll Cardiol 2006;48:576–578.

    PubMed  CAS  Google Scholar 

  152. Borer JS, Bacharach SL, Green MV, et al. Real-time radionuclide cineangiography in the noninvasive evaluation of global and regional left ventricular function at rest and during exercise in patients with coronary-artery disease. N Engl J Med 1977;296(15):839–844.

    PubMed  CAS  Google Scholar 

  153. Corbett JR, Dehmer GJ, Lewis SE, et al. The prognostic value of submaximal exercise testing with radionuclide ventriculography before hospital discharge in patients with recent myocardial infarction. Circulation 1981;64(3):535–544.

    PubMed  CAS  Google Scholar 

  154. Dehmer GJ, Lewis SE, Hillis LD, et al. Exercise-induced alterations in left ventricular volumes and the pressure-volume relationship: a sensitive indicator of left ventricular dysfunction in patients with coronary artery disease. Circulation 1981;63(5):1008–1018.

    PubMed  CAS  Google Scholar 

  155. Gibson RS, Watson DD, Craddock GB, et al. Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography. Circulation 1983; 68(2):321–336.

    PubMed  CAS  Google Scholar 

  156. Ritchie JL, Trobaugh GB, Hamilton GW, et al. Myocardial imaging with thallium-201 at rest and during exercise. Comparison with coronary arteriography and resting and stress electrocardiography. Circulation 1977;56(1):66–71.

    PubMed  CAS  Google Scholar 

  157. Coronary-artery bypass surgery in stable angina pectoris: Survival at two years. European Coronary Surgery Study Group. Lancet 1979;1(8122):889–893.

    Google Scholar 

  158. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation 1983;68(5):939–950.

    Google Scholar 

  159. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. N Engl J Med 1984;311(21):1333–1339.

    Google Scholar 

  160. Passamani E, Davis KB, Gillespie MJ, et al. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med 1985;312(25):1665–1671.

    PubMed  CAS  Google Scholar 

  161. Borer JS, Bacharach SL, Green MV, et al. Real-time radionuclide cineangiography in the noninvasive evaluation of global and regional left ventricular function at rest and during exercise in patients with coronary artery disease. N Engl J Med 1977;296(15):839–844.

    PubMed  CAS  Google Scholar 

  162. Corbett JR, Dehmer GJ, Lewis SE, et al. The prognostic value of submaximal exercise testing with radionuclide ventriculography before hospital discharge in patients with recent myocardial infarction. Circulation 1981;64(3):535–544.

    PubMed  CAS  Google Scholar 

  163. Dehmer GJ, Lewis SE, Hillis LD, et al. Exercise-induced alterations in left ventricular volumes and the pressure-volume relationship: a sensitive indicator of left ventricular dysfunction in patients with coronary artery disease. Circulation 1981;63(5):1008–1018.

    PubMed  CAS  Google Scholar 

  164. Gibson RS, Watson DD, Craddock GB, et al. Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography. Circulation 1983; 68(2):321–336.

    PubMed  CAS  Google Scholar 

  165. Ritchie JL, Trobaugh GB, Hamilton GW, et al. Myocardial imaging with thallium-201 at rest and during exercise. Comparison with coronary arteriography and resting and stress electrocardiography. Circulation 1977;56(1):66–71.

    PubMed  CAS  Google Scholar 

  166. Coronary-artery bypass surgery in stable angina pectoris: survival at two years. European Coronary Surgery Study Group. Lancet 1979;1(8122):889–893.

    Google Scholar 

  167. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation 1983;68(5):939–950.

    Google Scholar 

  168. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. N Engl J Med 1984;311(21):1333–1339.

    Google Scholar 

  169. Passamani E, Davis KB, Gillespie MJ, et al. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med 1985;312(26):1665–1671.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Research, Texas Heart Institute, Houston, TX, USA

    James J. Ferguson III MD

  2. Department of Cardiology, St. Luke’s Episcopal Hospital, Houston, TX, USA

    Dipsu D. Patel MD, MPH

  3. The University of Texas Health Science Center at Houston, Texas Heart Institute, Houston, TX, USA

    James T. Willerson MD

Authors
  1. James J. Ferguson III MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dipsu D. Patel MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James T. Willerson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Texas Health Science Center in Houston, Houston

    James T. Willerson MD (President, President-Elect and Medical Director) (President, President-Elect and Medical Director)

  2. Texas Heart Institute, Houston, TX, USA

    James T. Willerson MD (President, President-Elect and Medical Director) (President, President-Elect and Medical Director)

  3. Department of Cardiology, University of Maastricht, Masstricht, The Netherlands

    Hein J. J. Wellens MD (Emeritus Professor) (Emeritus Professor)

  4. Rasmussen Center for Cardiovascular Disease Prevention Cardiovascular Division, University of Minnesota, Minneapolis, MN, USA

    Jay N. Cohn MD (Professor of Medicine and Director) (Professor of Medicine and Director)

  5. Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA

    David R. Holmes Jr. MD (Consultant, Professor of Medicine and Scripps Professor) (Consultant, Professor of Medicine and Scripps Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag London Limited

About this chapter

Cite this chapter

Ferguson, J.J., Patel, D.D., Willerson, J.T. (2007). Medical Treatment of Stable Angina. In: Willerson, J.T., Wellens, H.J.J., Cohn, J.N., Holmes, D.R. (eds) Cardiovascular Medicine. Springer, London. https://doi.org/10.1007/978-1-84628-715-2_41

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-715-2_41

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-188-4

  • Online ISBN: 978-1-84628-715-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation